AKTUALITĀTES
   
49277

Pabeigts pret C hepatīta vakcīnas klīnisko pētījumu pirmais posms
Apskatīt komentārus (0)


08.11.2014


Pētījuma laikā zinātnieki novērtēja šīs vakcīnas drošumu un panesamību. Kā norādīts atskaitē, voluntieri (injekciju saņēma 15 veselie brīvprātīgie) labi pacieta injicēto vakcīnu. Pēc tam sekojošās asins analīzes uzrādīja, ka eksperimentālā substance veicināja antivielu pret C hepatītu  izstrādi organismā, kas apliecināja šīs substances augsto potenciālu. Patlaban zinātnieki strādā pie nākamā klīnisko pētījumu posma. Plāno, ka pētījuma otrās fāzes rezultāti tiks iegūti 2016. gadā. Taču pagaidām nav zināms, kad jaunā izstrādne parādīsies tirgū un cik tā maksās.
********************
Avots: "A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory" | http://stm.sciencemag.org/content/6/261/261ra153 |
A protective vaccine against hepatitis C virus (HCV) remains an unmet clinical need. HCV infects millions of people worldwide and is a leading cause of liver cirrhosis and hepatocellular cancer. Animal challenge experiments, immunogenetics studies, and assessment of host immunity during acute infection highlight the critical role that effective T cell immunity plays in viral control. In this first-in-man study, we have induced antiviral immunity with functional characteristics analogous to those associated with viral control in natural infection, and improved upon a vaccine based on adenoviral vectors alone. We assessed a heterologous prime-boost vaccination strategy based on a replicative defective simian adenoviral vector (ChAd3) and modified vaccinia Ankara (MVA) vector encoding the NS3, NS4, NS5A, and NS5B proteins of HCV genotype 1b. Analysis used single-cell mass cytometry and human leukocyte antigen class I peptide tetramer technology in healthy human volunteers. We show that HCV-specific T cells induced by ChAd3 are optimally boosted with MVA, and generate very high levels of both CD8+ and CD4+ HCV-specific T cells targeting multiple HCV antigens. Sustained memory and effector T cell populations are generated, and T cell memory evolved over time with improvement of quality (proliferation and polyfunctionality) after heterologous MVA boost. We have developed an HCV vaccine strategy, with durable, broad, sustained, and balanced T cell responses, characteristic of those associated with viral control, paving the way for the first efficacy studies of a prophylactic HCV vaccine. 

  


 
      Atpakaļ

atstāj tukšu: atstāj tukšu:
vārds:




Ievadiet drošības kodu:

Visual CAPTCHA



Gaismas iela 19 k-8, Ķekava, Ķekavas pagasts, Ķekavas novads, LV-2123, Latvija

Logo +371 26062077
Logo apvieniba@apvienibahiv.lv